Glimepiride USP and Metformin Hydrochloride USP
Composition: Each Film Coated Tablet Contains Glimepiride USP 2 mg and Metformin Hydrochloride USP 500 mg as Extended Release.
Indication: This combination is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Glimepiride and Metformin is appropriate or in cases where Glimepiride/Metformin mono-therapy does not result in adequate glycemic control.
Dosage & administration: The initial recommended dose of Glimepiride and Metformin combination tablet once daily with breakfast or first main meal of the day. Starting dose for patients inadequately controlled on Glimepiride or Metformin monotherapy is Limpet-M 1 once daily, and gradually titrated after assessing the therapeutic response. Titration: The daily dose must be titrated in increments of 1 tablet. The maximum recommended dose per day is 8 mg Glimepiride and 2000 mg Metformin. When switching from combination therapy of Glimepiride plus Metformin to separate tablets, Glimepiride and Metformin should be administered separately on the basis of dosage currently being taken. When Glimepiride and Metformin combination tablet is used in combination or with insulin, a lower dose of the Glimepiride or insulin may be required to reduce the risk of hypoglycemia. Or, as directed by the registered physician.
Use in pregnancy and lactation: The use of this combination is not recommended in pregnancy & lactation.
Packing: Each box contains 3 x 7's tablets in blister pack.
© Copyright Drug International Ltd. 2023 Designed and Developed by ATI Limited.